Kyverna Therapeutics announced its trial design is FDA-aligned and hosted a virtual KOL event.
1 report, 1 independent
Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Kyverna Therapeutics announced its trial design is FDA-aligned and hosted a virtual KOL event.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Kyverna hosts events featuring Srikanth Muppidi and Aiden Haghikia, who is affiliated with Hannover Medical School.Sub-event
Kyverna's trial design received FDA alignment, accompanied by a virtual KOL event.1 source
Keep exploring
The entities involved
Related events
- Nkarta is seeking protocol amendments for its clinical trials under the FDA.
- Experimental therapies require approval from the FDA.
- SynAct Pharma AB is seeking discussion with the FDA regarding the design of its Phase 3 clinical trials.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- FDA placed a clinical hold on Phase 2/3 trials for SK Biopharm on September 1, 2026.
Coverage
Newest first; wire copies grouped- GlobeNewswireKyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event KYV-101 has the potential to deliver durable, drug-fr